Shanghai Fudan Zhangjiang Bio Pharmaceutical Co ( (HK:1349) ) has issued an update.
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. has announced a final cash dividend of RMB 0.03 per share for the year ended December 31, 2024, with the payment to be made on August 26, 2025. This announcement reflects the company’s stable financial performance and commitment to returning value to shareholders, while also detailing the applicable withholding tax rates for different types of shareholders.
More about Shanghai Fudan Zhangjiang Bio Pharmaceutical Co
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. operates in the biopharmaceutical industry, focusing on the development and commercialization of innovative drugs and therapies. The company is known for its research-driven approach and commitment to advancing healthcare solutions.
See more insights into 1349 stock on TipRanks’ Stock Analysis page.